Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 59Cyclophosphamide 29fludarabine phosphate 20Bortezomib 16Filgrastim 15Tacrolimus 12Mycophenolic Acid 12Methotrexate 12Radiotherapy 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 11Antilymphocyte Serum 11Whole-Body Irradiation 10fludarabine 8Etoposide 8venetoclax 7sargramostim 7idelalisib 7ibritumomab tiuxetan 7Melphalan 7Lenalidomide 7Cord Blood Stem Cell Transplantation 7Busulfan 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Granulocyte Colony-Stimulating Factor 6obinutuzumab 5Gemcitabine 5umbralisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Follicular × LFB-R603 × Clear all
NCT04806035 2024-07-31

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

TG Therapeutics, Inc.

Phase 1 Terminated
21 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡